BR55: A lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis

Investigative Radiology

Volumn 45, Issue 2, 2010, Pages 89-95

  Pochon, Sibylle ^a   Tardy, Isabelle ^a   Bussat, Philippe ^a   Bettinger, Thierry ^a   Brochot, Jean ^a   Von Wronski, Mathew ^b   Passantino, Lisa ^b   Schneider, Michel ^a  

^a Bracco Suisse SA   (Switzerland)

^b Bracco Research USA   (United States)

Author keywords

Angiogenesis; BR55; Tumor detection; Ultrasound targeted contrast agent; VEGFR2 KDR

Indexed keywords

BR 55; ECHO CONTRAST MEDIUM; LIPOPEPTIDE; UNCLASSIFIED DRUG; VASCULOTROPIN C;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOTINYLATION; BREAST TUMOR; CANCER DIAGNOSIS; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IC 50; IMMUNOCYTOCHEMISTRY; MICROBUBBLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 74949107510     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181c5927c     Document Type: Article

References (33)

1. Dayton PA, Rychak JJ. Molecular ultrasound imaging using microbubbles contrast agents. Front Biosci. 2007;12:5124-5142.
2. Tardy I, Pochon S, Theraulaz M, et al. In vivo ultrasound imaging of thrombi using a target-specific contrast agent. Acad Radiol. 2002;9(suppl 2):S294-S296.
3. Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1-18.
4. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005; 438:967-974.
5. Kerbel RS. Molecular origins of cancer tumor angiogenesis. N Engl J Med. 2008;358:2039-2049.
6. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438: 932-936.
7. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol. 2006;39:469-478.
8. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011-1127.
9. Jain RK. Normalizing of tumor vasculature: an emerging concept in antian-giogenic therapy. Science. 2005;307:58-62.
10. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391-400.
11. Reinacher-Schick A, Pohl M, Schmiegel W. Drug Insight: antiangiogenic therapies for gastrointestinal cancers\-focus on monoclonal antibodies. Nat Clin Pract Gastroenterol Hepatol. 2008;5:250-267.
12. Longo R, Gasparini G. Anti-VEGF therapy: the search for clinical biomark-ers. Expert Rev Miol Diagn. 2008;8:305-314.
13. Raatschen HJ, Fu Y, Brasch RC, et al. In vivo monitoring of angiogenesis inhibitory treatment effects by dynamic contrast-enhanced computed tomography in a xenograft tumor model. Invest Radiol. 2009;44:265-270.
14. Lijowski M, Caruthers S, Hu G, et al. High sensitivity: high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model. Invest Radiol. 2009;44:15-22.
15. Virostko J, Xie J, Hallahan DE, et al. A molecular imaging paradigm to rapidly profile response to angiogenesis-directed therapy in small animals. Mol Imaging Biol. 2009;11:204-212.
16. Korpanty G, Carbon JG, Grayburn PA, et al. Monitoring response to anti-cancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res. 2007;13:323-330.
17. Willmann JK, Lutz AM, Paulmurugan R, et al. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology. 2008;248:936-944.
18. Willmann JK, Paulmurugan R, Chen K, et al. US imaging of tumor angio-genesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology. 2008;246:508-518.
19. Palmowski M, Morgenstern B, Hauff P, et al. Pharmacodynamics of strepta-vidin-coated cyanoacrylate microbubbles designed for molecular ultrasound imaging. Invest Radiol. 2008;43:162-169.
20. Palmowski M, Huppert J, Ladewig G, et al. Molecular profiling of angiogen-esis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects. Mol Cancer Ther. 2008;7:101-109.
21. Lee DL, Lyshchik A, Huamani J, et al. Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasono-graphic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model. J Ultrasound Med. 2008;27:855-866.
22. Lyshchik A, Fleischer AC, Huamani J, et al. Molecular imaging of vascular endothelial growth factor receptor 2 expression using targeted contrast-enhanced high-frequency ultrasonography. J Ultrasound Med. 2007;26:1575-1586.
23. Rychak J, Graba J, Cheung AM, et al. Microultrasound molecular imaging of vascular endothelial growth factor 2 in a mouse model of tumor angiogenesis. Mol Imaging. 2007;6:289-296.
24. Shrivastava A, von Wronski MA, Sato AK, et al. A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases. Protein Eng Des Sel. 2005;18:417-424.
25. Pillai R, Marinelli ER, Swenson RE. A Flexible Method for preparation of peptide homo-and heterodimers functionalized with affinity probes, chelating ligands, and latent conjugating groups. Biopolymers (Peptide Sci). 2006;84: 576-585.
26. Pillai R, Marinelli E, Fan H, et al. A phospholipid-PEG2000-conjugate of a KDR-targeting heterodimer peptide for contrast enhanced ultrasound imaging of angiogenesis. Bioconjugate Chem. In press.
27. Backer MV, Backer JM. Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of shiga-like toxin-VEGF fusion proteins. Bio-conjugate Chem. 2001;12:1066-1073.
28. McGabhann F, Popel A. Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am J Physiol Heart. 2004;286:153-164.
29. Klibanov AL, Gu H, Wojdyla JK, et al. Attachment of ligands to gas-filled microbubbles via PEG spacer and lipid residues anchored at the interface. In Proceedings of the 26th International Symposium on Controlled Release of Bioactive Materials, Boston, MA, June 20-25 1999; Controlled Release Society. 1999:124-125.
30. Weller GE, Villanueva FS, Klibanov AL, et al. Modulating targeted adhesion of an ultrasound contrast agent to dysfunctional endothelium. Ann Biomed Eng. 2002;30:1012-1019.
31. Korpanty G, Grayburn PA, Shohet RV, et al. Targeting vascular endothelium with avidin microbubbles. Ultrasound Med Biol. 2005;31:1279-1283.
32. Hauff P, Reinhardt M, Briel A, et al. Molecular targeting of lymph nodes with L-selectin ligand-specific US contrast agent: a feasibility study in mice and dogs. Radiology. 2004;231:667-673.
33. Chinol M, Casalini P, Maggiolo M, et al. Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. Br J Cancer. 1998;78:189-197